Trial Profile
Effect of Pregabalin on Costs and Consequences in Patients with Refractory Severe Generalized Anxiety Disorder and Concomitant Severe Symptoms of Depression in Daily Medical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2011
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Generalised anxiety disorder; Major depressive disorder
- Focus Therapeutic Use
- Sponsors Pfizer
- 21 Jan 2011 New trial record
- 09 Nov 2010 Results presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research